Dataset Information


Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure.

ABSTRACT: Drug-induced liver injury (DILI) limits the development and application of many therapeutic compounds and presents major challenges to the pharmaceutical industry and clinical medicine. Acetaminophen-containing compounds are among the most frequently prescribed drugs and are also the most common cause of DILI. Here we describe a pharmacological strategy that targets gap junction communication to prevent amplification of fulminant hepatic failure and acetaminophen-induced hepatotoxicity. We demonstrate that connexin 32 (Cx32), a key hepatic gap junction protein, is an essential mediator of DILI by showing that mice deficient in Cx32 are protected against liver damage, acute inflammation and death caused by liver-toxic drugs. We identify a small-molecule inhibitor of Cx32 that protects against liver failure and death in wild-type mice when co-administered with known hepatotoxic drugs. These findings indicate that gap junction inhibition could provide a pharmaceutical strategy to limit DILI and improve drug safety.


PROVIDER: S-EPMC3609650 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC6128234 | BioStudies
2017-02-12 | GSE76098 | GEO
2020-01-01 | S-EPMC7261084 | BioStudies
1000-01-01 | S-EPMC6123534 | BioStudies
1000-01-01 | S-EPMC6162937 | BioStudies
2016-01-01 | S-EPMC5414847 | BioStudies
2016-01-01 | S-EPMC5285516 | BioStudies
2017-01-01 | S-EPMC5483505 | BioStudies
2016-01-04 | E-GEOD-59602 | ArrayExpress
1999-01-01 | S-EPMC1220152 | BioStudies